Provide feedbackProvide feedback

« Back

Merck, Abide Therapeutics to collaborate on treatments for type 2 diabetes, metabolic diseases

Wednesday, May 22 2013 | Comments
Evidence Grade 0 What's This?
Merck and Abide Therapeutics Inc. agreed to jointly discover, develop, and market small molecule therapies directed against three novel targets to treat metabolic diseases with a focus on type 2 diabetes.

Under the terms of the agreement, Abide Therapeutics is eligible to receive an up-front payment, research funding, and potential milestone payments for up to $430 million for three products. Merck will receive worldwide marketing rights to any products that are developed under the collaboration, while Abide Therapeutics is entitled to receive royalty payments on global sales from any such products.

San Diego-based Abide Therapeutics is a biopharmaceutical company focused on innovative approaches to selectively target a group of enzymes known as serine hydrolases, which are enzymes that play a key regulatory role in human physiological processes.

Print  |  E-mail

Comments

Be the first to write a comment for this article!

You must be logged in to post a comment.